LI Yanjin
1. Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Kunming Medical University, Kunming 650106, ChinaXIAO Liying
1. Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Kunming Medical University, Kunming 650106, ChinaWU Daoxiong
2. Department of Clinical Laboratory, the Second Affiliated Hospital of Kunming Medical University, Kunming 650106GUAN Rong
1. Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Kunming Medical University, Kunming 650106, ChinaYAN Chunlang
1. Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Kunming Medical University, Kunming 650106, ChinaLEI Wen
1. Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Kunming Medical University, Kunming 650106, China1. Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Kunming Medical University, Kunming 650106, China. 2. Department of Clinical Laboratory, the Second Affiliated Hospital of Kunming Medical University, Kunming 650106
R-33
Pulmonary hypertension ( PH ) is a progressive disease characterized by pulmonary vascular remodeling. Current treatments for PH remain suboptimal, and there is an urgent need to better decipher the underlying pathomechanisms to identify new therapeutic targets. MicroRNA (miRNA) are key components in the post-transcriptional machinery that mediates cellular functions and mainly act by regulating the expression of downstream target genes.Numerous in vivo and in vitro studies have demonstrated the involvement of miRNA and their regulators in PH development.However, there is no unified model for the mechanism of miRNA’ s regulation of pulmonary vascular remodeling. Therefore, this article provides a review on the mechanisms of miRNA in PH characterized in recent years.
